Prf Technologies Ltd (PRFX) - News Archive

In a groundbreaking move that sets the stage for expansive growth, PainReform Ltd (NASDAQ: PRFX) has announced its strategic acquisition of DeepSolar, a pioneering company specializing in AI-driven solar analytics. This...

DeepSolar s Strategic Leap: Merging Solar Analytics with AI and PharmaceuticalsIn a remarkable intersection of technological innovation and renewable energy, DeepSolar has positioned itself at the forefront of a burgeon...

In the realm of pharmaceutical innovation, PainReform Ltd. stands out as a clinical-stage specialty pharmaceutical company dedicated to reformulating established therapeutics for enhanced therapeutic outcomes. Recently,...

PainReform Reveals Promising Topline Data for PRF-110 in Phase 3 Clinical Trial Tel Aviv, Israel PainReform Ltd. (Nasdaq: PRFX), a clinical-stage pharmaceutical company focused on the reformulation of established therap...

An Ongoing Battle for Compliance: PainReform Ltd’s Struggles on the Nasdaq ExchangeAs of November 7, 2024, PainReform Ltd. (NASDAQ: PRFX), a clinical-stage specialty pharmaceutical company based in Tel Aviv, has encount...

Navigating Post-Surgical Pain Management Post-surgical pain management is a critical component of patient care, directly influencing recovery and overall outcomes. PainReform Ltd. a clinical-stage specialty pharmaceutic...

: The PainReform Bunionectomy Study offers significant insights into the management of post-operative pain through a novel delivery method of PRF-110. This article reviews the study findings, comparing traditional pain...

The pursuit of effective pain management solutions has led to innovative developments in the pharmaceutical landscape. PainReform Ltd., a clinical-stage specialty pharmaceutical company, has emerged at the forefront of...

PainReform, an innovative leader in drug delivery solutions, has recently announced a significant milestone in the development and successful manufacturing of new formulations aimed at providing enhanced postoperative c...

Emerging Safety Data Show PRF-110’s Potential for Expanded Surgical Applications TEL AVIV, Israel, Aug. 07, 2024 PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company dedicated to the reformu...

PainReform, a biopharmaceutical company focused on developing innovative drug delivery systems, has announced a significant advancement in its manufacturing process for PRF-110, a product designed for pain management. T...

PainReform, a pharmaceutical company specializing in pain management, has recently made significant progress in its Phase 3 clinical trials for PRF-110, a novel drug aimed at providing extended postoperative pain relief...

PainReform Ltd Announces Non-Compliance with Nasdaq Listing RequirementsPainReform Ltd, a clinical-stage specialty pharmaceutical company, recently received a letter from the Nasdaq Listing Qualifications indicating tha...

IntroductionIn a recent interview with Proactiveinvestors.com, PainReform Ltd. s CEO, Ilan Hadar, shed light on the latest developments surrounding PRF-110 and its potential to address the concerning opioid epidemic. As...

TEL AVIV, Israel - PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, has recently announced the successful closing of its public...

PainReform s Public Offering Signals Growth in Clinical-Stage Pharmaceutical IndustryIn a recent announcement, PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company, unveiled the pricing of i...

In what is undoubtedly a significant breakthrough for PainReform Ltd, the non-opiate topical treatment of the Israel-based specialty pharmaceutical company, PRF-110, has demonstrated superior in-vitro release (IVR) rate...

In the realm of modern medicine, the ever-elusive quest for effective pain management techniques has long been a topic of intense research and development. However, PainReform, a pioneering pharmaceutical company, may b...

In a groundbreaking development in the field of postoperative pain management, PainReform has recently unveiled the astounding results of their head-to-head comparison between PRF-110 and the current market-leading post...

PainReform Ltd Announces Exercise of Warrants, Garnering Approximately $1.3 Million in Gross ProceedsTEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) PainReform Ltd (Nasdaq: PRFX), a leading clinical-stage specialty pha...